Actively Recruiting
Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD
Led by Texas A&M University · Updated on 2026-04-24
200
Participants Needed
2
Research Sites
226 weeks
Total Duration
On this page
Sponsors
T
Texas A&M University
Lead Sponsor
M
Medical University of South Carolina
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test the efficacy of a novel integrative cognitive-behavioral intervention in patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD). Specific Aim 1: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing alcohol frequency (percent days drinking) and quantity (drinks per drinking day) as measured by the Timeline Follow-Back (TLFB). Specific Aim 2: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5). Specific Aim 3: Use ecological momentary assessment (EMA) to evaluate intervention effects on daily alcohol-related cognitions and behaviors through real-time associations with PTSD symptomatology and distress tolerance. Researchers will compare integrative CPT+RP with RP-alone to see if CPT+RP is more efficacious in reducing alcohol use and PTSD symptom severity.
CONDITIONS
Official Title
Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any gender identity, any race or ethnicity, 18 years of age or older
- Able to provide written informed consent
- Ability to understand English
- Meet DSM-5 criteria for current moderate to severe alcohol use disorder (at least 4 criteria) in the past month
- Have at least 3 to 4 heavy drinking days per week (4+ drinks for women, 5+ drinks for men) in the last 30 days, or more than 14 drinks per week for females or more than 21 drinks per week for males for at least 2 weeks in the last 30 days
- Meet DSM-5 criteria for current PTSD as assessed by the Clinician Administered PTSD Scale (CAPS-5)
- May have mood or anxiety disorders except bipolar disorder
- Participants on psychotropic medications must be on a stable dose for at least 4 weeks before starting the study
You will not qualify if you...
- History of or current psychotic disorder or bipolar disorder
- Imminent risk of suicidal or homicidal behavior
- Psychotropic medications initiated within the past 4 weeks
- Acute alcohol withdrawal indicated by CIWA-Ar scores greater than 8
- Pregnancy or breastfeeding for women
- Currently enrolled in evidence-based behavioral treatment for AUD or PTSD
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Actively Recruiting
2
Texas A&M University
College Station, Texas, United States, 77843
Actively Recruiting
Research Team
A
Anka A Vujanovic, Ph.D.
CONTACT
S
Sudie E Back, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here